Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study Meeting Abstract
| Authors: | Carbone, D. P.; Morgensztern, D.; Le Moulec, S.; Santana-Davila, R.; Ready, N.; Hann, C. L.; Glisson, B. S.; Dowlati, A.; Rudin, C. M.; Lally, S.; Yalamanchili, S.; Wolf, J.; Govindan, R.; Besse, B. |
| Abstract Title: | Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 439s |
| Language: | English |
| ACCESSION: | WOS:000442916003105 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.8507 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 8507 -- Source: Wos |
